Advertisement

Effect of Older vs Younger Age on Anthropometric and Metabolic Variables During Treatment of Psychotic Depression With Sertraline Plus Olanzapine: The STOP-PD II Study

Published:November 15, 2020DOI:https://doi.org/10.1016/j.jagp.2020.11.003

      HIGHLIGHTS

      • This study examined the effect of older versus younger age on change in anthropometric and metabolic measures during extended treatment of psychotic depression with sertraline plus olanzapine.
      • Among patients with psychotic depression, acute and stabilization treatment with sertraline plus olanzapine was associated with increase in weight and total cholesterol, but the trajectory of these increases was less in older compared with younger participants. Weight gain in older participants appeared to be restoration of weight lost during the episode of depression, whereas weight gain in younger participants was not.
      • Older patients with psychotic depression experience less increase in weight and total cholesterol than their younger counterparts during acute and stabilization treatment with sertraline plus olanzapine.

      ABSTRACT

      Objective

      To examine the effect of older versus younger age on change in anthropometric and metabolic measures during extended treatment of psychotic depression with sertraline plus olanzapine.

      Methods

      Two hundred and sixty-nine men and women aged 18–85 years with an episode of psychotic depression were treated with open-label sertraline plus olanzapine for up to 12 weeks. Participants who remained in remission following an 8-week stabilization phase were eligible to participate in a 36-week randomized controlled trial (RCT) that compared the efficacy and tolerability of sertraline plus olanzapine with sertraline plus placebo. Weight, waist circumference and plasma lipids, glucose, HbA1c, and insulin were measured at regular intervals during the acute, stabilization and randomized phases of the study. Linear mixed models were used to analyze the trajectories of anthropometric and metabolic measures.

      Results

      Participants aged 60 years or older experienced less weight gain and less increase in cholesterol during the combined acute and stabilization phases of the study compared with those aged 18–59 years. At the acute-stabilization termination visit, mean weight in older participants was 6.5 lb. less than premorbid weight, whereas it was 17.9 lb. more than premorbid weight in younger participants. In the RCT, there was a significant interaction of treatment and age group for the trajectory of weight, but the post hoc tests that compared age groups within each treatment arm were not statistically significant. There were no clinically significant differences between younger and older participants in glycemic measures.

      Conclusion

      Older patients with psychotic depression experienced less increase in weight and total cholesterol than their younger counterparts during acute and stabilization treatment with sertraline plus olanzapine. In the older group, weight gained during the acute and stabilization phases appeared to be partial restoration of weight lost during the index episode of depression, whereas weight gain in younger participants was not.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Geriatric Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kroessler D
        Relative efficacy rates for therapies of delusional depression.
        Convulsive Ther. 1985; 1: 173-182
        • Farahani A
        • Correll CU
        Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment.
        J Clin Psychiatry. 2012; 73: 486-496
        • Flint AJ
        • Meyers BS
        • Rothschild AJ
        • et al.
        Effect of continuing olanzapine versus placebo on relapse among patients with psychotic depression in remission: the STOP-PD II randomized clinical trial.
        JAMA. 2019; 322: 622-631
        • Brodaty H
        • Luscombe G
        • Parker G
        • et al.
        Increased rate of psychosis and psychomotor change in depression with age.
        Psychol Med. 1997; 27: 1205-1213
        • Jääskeläinen E
        • Juola T
        • Korpela H
        • et al.
        Epidemiology of psychotic depression – systematic review and meta-analysis.
        Psychol Med. 2018; 48: 905-918
        • Hildrum B.
        • Mykletun A.
        • Hole T.
        • et al.
        Age-specific prevalence of the metabolic syndrome defined by the international diabetes federation and the national cholesterol education program: the Norwegian HUNT 2 study.
        BMC Public Health. 2007; 7: 220
        • Meyers BS
        • Flint AJ
        • Rothschild AJ
        • et al.
        A double- blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression - the STOP-PD study.
        Arch Gen Psychiatry. 2009; 66: 838-847
        • Bingham K
        • Meyers BS
        • Mulsant BH
        • et al.
        Stabilization treatment of remitted psychotic depression: the STOP-PD study.
        Acta Psychiatr Scand. 2018; 138: 267-273
        • Flint AJ
        • Rothschild AJ
        • Whyte EM
        • et al.
        Sustaining remission of psychotic depression: rationale, design and methodology of STOP-PD II.
        BMC Psychiatry. 2013; 13: 38-49
        • First MB
        • Spitzer RL
        • Gibbon M
        • et al.
        Structured Clinical Interview for DSM-IV-TR Axis I Disorders - Patient Edition (SCID-I/P).
        Biometrics Research Department, New York2001
        • Hamilton M
        A rating scale for depression.
        J Neurol Neurosurg Psychiatry. 1960; 23: 56-62
        • Jorm AF
        The informant questionnaire on cognitive decline in the elderly (IQCODE): a review.
        Int Psychogeriatrics. 2004; 16: 275-293
        • Folstein M
        • Folstein S
        • McHugh P
        “Mini mental state”: a practical method for grading the cognitive state of patients for the clinician.
        J Psychiatr Res. 1975; 12: 189-198
        • Matthews DR
        • Hosker JP
        • Rudenski AS
        • et al.
        Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.
        Diabetologia. 1985; 28: 412-419
        • Miller MD
        • Paradis CF
        • Houck PR
        • et al.
        Rating chronic medical illness burden in geropsychiatric practice and research: application of the cumulative illness rating scale.
        Psychiatry Res. 1992; 41: 237-248
        • Little RJ
        • Rubin DB
        Statistical Analysis With Missing Data.
        John Wiley & Sons, Hoboken, New Jersey2014
        • Bates D
        • Maechler M
        • Bolker B
        • et al.
        Fitting linear mixed-effects models using lme4.
        J Stat Software. 2015; 67: 1-48
        • Holm S
        A simple sequentially rejective multiple test procedure.
        Scand J Stat. 1979; 6: 65-70
        • Bak M
        • Fransen A
        • Janssen J
        • et al.
        Almost all antipsychotics result in weight gain: a meta-analysis.
        PLoS One. 2014; 9: e94112
        • Pillinger T
        • McCutcheon RA
        • Vano L
        • et al.
        Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis.
        Lancet Psychiatry. 2020; 7: 64-77
        • Wijkstra J
        • Burger H
        • van den Broek WW
        • et al.
        Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine.
        Acta Psychiatr Scand. 2010; 121: 190-200